Original Article
Outbreak of Varicella at a Day-Care Center despite Vaccination
N Engl J Med 2002; 347:1909-1915December 12, 2002
- Abstract
Background
In seven studies of the effectiveness of the varicella vaccine conducted since it was licensed, the effectiveness was 71 to 100 percent against disease of any severity and 95 to 100 percent against moderate and severe disease. We investigated an outbreak of varicella in a population of children with a high proportion of vaccinees who were attending a day-care center in a small community in New Hampshire.
Methods
Using standardized questionnaires, we collected information about the children's medical and vaccination history from parents and health care providers. The analysis of the effectiveness of the vaccine and of risk factors for vaccine failure was restricted to children who were enrolled in the day-care center continuously during the outbreak and attended for one week or more and who were cared for in the building that represented the epicenter of the outbreak, since transmission was not documented in a second building.
Results
Varicella developed in 25 of 88 children (28.4 percent) between December 1, 2000, and January 11, 2001. The index case occurred in a healthy child who had been vaccinated three years previously and who infected more than 50 percent of his classmates who had no history of varicella. The effectiveness of the vaccine was 44.0 percent (95 percent confidence interval, 6.9 to 66.3 percent) against disease of any severity and 86.0 percent (95 percent confidence interval, 38.7 to 96.8 percent) against moderate or severe disease. Children who had been vaccinated three years or more before the outbreak were at greater risk for vaccine failure than those who had been vaccinated more recently (relative risk, 2.6 [95 percent confidence interval, 1.3 to 5.3]).
Conclusions
In this outbreak, vaccination provided poor protection against varicella, although there was good protection against moderate or severe disease. A longer interval since vaccination was associated with an increased risk of vaccine failure. Breakthrough infections in vaccinated, healthy persons can be as infectious as varicella in unvaccinated persons.
Media in This Article
Figure 1
Cases of Varicella in a New Hampshire Day-Care Center in December 2000 and January 2001, According to the Vaccination Status of the Children and the Date of Onset of Rash.Table 1
Characteristics of All Children and Children in Building A Who Attended the Day-Care Center for at Least One Week during the Varicella Outbreak Period, December 2000 through January 2001.Article Activity
- Article
Since the licensure of the varicella vaccine in 1995, seven investigations of the effectiveness of the vaccine have been published.1-6 Effectiveness ranged from 71 to 100 percent against varicella disease of any severity and 95 to 100 percent against moderate-to-severe varicella disease. Those findings are similar to results from prelicensure trials that used both the currently formulated vaccine and other formulations of the Oka-strain varicella virus to immunize children.7-14 In the United States, there is clear evidence from three active surveillance sites that the incidence of varicella disease and the rate of related hospitalizations have declined by 80 percent since the introduction of the vaccine.15
Although the vaccine affords excellent protection against moderate and severe varicella, a modified form of varicella develops in some vaccinated persons after exposure to someone with an infectious case. By definition, these breakthrough cases occur more than 42 days after vaccination and are usually caused by wild-type virus. Rashes occurring less than 14 days after vaccination are typically due to previously incubating wild-type disease, and rashes occurring 14 to 42 days after vaccination may be attributable to either strain and can be classified only by molecular typing. Breakthrough disease is typically mild, with fewer lesions (usually fewer than 50),11,12,16,17 complications, and systemic symptoms.17,18 To date, there is no evidence of an increase over time in the rate of breakthrough disease that would suggest waning immunity after vaccination. We describe an outbreak of varicella at a day-care center in New Hampshire, where vaccination coverage in 2000 was 66 percent19 — similar to the national average of 68 percent.
Methods
Study Setting
The outbreak occurred in a private, licensed day-care center in a small community (population, 4500) near Concord, New Hampshire, that enrolled 92 children and employed 14 staff members. The day-care center was housed in two separate buildings approximately 20 yards apart. Building A housed children in the preschool, kindergarten, and before- and after-school programs, who mixed freely and shared common air flow. Building B, which housed the younger children, provided less opportunity for transmission, since children spent most of the day in one of four separate classrooms. Occasionally, parents with children in both buildings would have one child with them when they collected a sibling in the other building.
Case Definition
We defined a case of natural varicella as an illness involving a pruritic, maculopapulovesicular rash with no other apparent cause beginning from December 1, 2000, through January 11, 2001, in a child attending the day-care center who had not received varicella vaccine or who had been vaccinated less than 14 days before the onset of rash. Breakthrough disease was defined as varicella in a child who had been vaccinated more than 42 days before the onset of rash. Illness was classified as mild (fewer than 50 lesions without complications), moderate (51 to 500 lesions), or severe (more than 500 lesions or the occurrence of any serious complications, such as varicella pneumonitis, encephalitis, fever [temperature, >38.5°C] for five days, hospitalization, or death). Children were considered to have asthma if they had a reported history of asthma and were being treated with any asthma medication.
Questionnaires
A self-administered questionnaire for parents was used to collect demographic information, medical and vaccination history, and information about health care providers for all children, as well as detailed information about illnesses and exposure to varicella outside the day-care center for children in whom illness involving a rash developed on or after November 1, 2000 (one month before the onset of the index case). We distributed questionnaires to health care providers to verify the child's health status, medication and vaccination history, and remote or recent history of varicella.
Laboratory Investigations
An enzyme-linked immunosorbent assay testing for IgG antibody against whole-cell varicella–zoster virus in a filter-paper blood spot from a finger prick was offered for any child who did not have a history of either varicella disease or varicella vaccination. Children with rash were offered testing to determine whether varicella–zoster virus was present and to distinguish wild-type virus from the strain in the vaccine. Polymerase-chain-reaction analysis and restriction-fragment–length polymorphism analysis of varicella–zoster virus were performed with the use of the ORF62 primer pair according to the methods of Loparev et al.20 and LaRussa et al.21
Investigation of Secondary Cases and Surveillance
The secondary attack rate from the index case was calculated as the proportion of susceptible, exposed children who were in Building A on at least one day when transmission could have occurred — that is, November 29 through December 1 — in whom varicella developed within 21 days after exposure. Enhanced surveillance for illness involving rash was continued at the day-care center until one incubation period (21 days) after the last case was identified.
Vaccine Lots, Storage, and Handling
Lot numbers were verified with the manufacturer, and the expiration date for each lot of vaccine was obtained. Information from periodic evaluations of the storage and handling of vaccine in the offices of vaccine providers, which have been conducted by the health department since 1995, were reviewed, and further evaluations were undertaken as a result of the outbreak.
Statistical Analysis
Data were entered into Epi Info (version 6.04b, Centers for Disease Control and Prevention) and analyzed with the use of SAS software (release 8.0, SAS Institute). Fisher's exact test was used for the comparison of proportions, and the exact Wilcoxon rank-sum test was used for the comparison of medians. All P values are two-sided, with a significance level of P<0.05. Because the numbers were small, multivariate models were unstable, and their results are not presented.
Vaccine effectiveness rates and 95 percent confidence intervals were calculated by the cohort method.22 We excluded children with a history of varicella disease and children less than 12 months of age. We calculated the attack rates in unvaccinated children (ARU) and vaccinated children (ARV); we then estimated the percentage effectiveness of the vaccine as [(ARU – ARV) ÷ ARU] × 100. The effectiveness of the vaccine against moderate-to-severe disease was calculated by classifying mild cases as noncases. Analysis of vaccine effectiveness and analysis of risk factors were limited to children in Building A (the epicenter of the outbreak) who were enrolled throughout the outbreak period and had attended day care for at least one week during the exposure period (from two days before the onset of rash in the index case — November 29, 2000 — to the date of the onset of rash in the last case — January 11, 2001). Children were considered to have been vaccinated if more than 42 days had elapsed since vaccination. Two children who were vaccinated on December 26, 2000, were classified as unvaccinated. Vaccination coverage at the start of the outbreak was defined as the proportion of children eligible for vaccination (at least 12 months of age and without a history of varicella) who had received the vaccine.
Results
Study Subjects
Between December 1, 2000, and January 11, 2001, 92 children were enrolled in the day-care center. Four children attended for less than one week and were excluded from the analyses. Parents and health care providers returned questionnaires for 88 attendees (100 percent). Attendees ranged in age from 6 months to 8.9 years (median, 4.1 years) at the start of the outbreak; 61 of them (69.3 percent) were boys. At the start of the outbreak, vaccination coverage among children old enough to be eligible was 73.1 percent (49 of 67). Lot numbers of vaccine were verified for 93.9 percent of vaccinated children (46 of 49). Children were vaccinated during five different years (1996 to 2000) with at least 33 different lots of vaccine administered by 28 different health care providers. There was no evidence that any child had received expired vaccine.
Building A
Fifty-two of the 88 children (59.1 percent) attended the day-care center in Building A. Their median age was 5.3 years (range, 3.5 to 8.9), 32 of them (61.5 percent) were boys, and 15 of them (28.8 percent) had a history of varicella. Vaccination coverage among children who were old enough to receive the vaccine and who had no history of varicella was 73.0 percent (27 of 37). Characteristics of children in the day-care center are summarized in Table 1Table 1
Characteristics of All Children and Children in Building A Who Attended the Day-Care Center for at Least One Week during the Varicella Outbreak Period, December 2000 through January 2001..Investigation of the Index Case
The index patient was a healthy, vaccinated, four-year-old boy who had an onset of rash on December 1, 2000, approximately three years after vaccination (November 14, 1997). He attended the day-care center on the two days before the onset of rash and briefly on the morning on which his rash erupted, before he was taken home. He was moderately ill, with a generalized rash consisting of approximately 150 vesicular lesions and a temperature of 102.5°F (39.2°C), remained bedridden for one day, and had no complications. His only known exposure to varicella–zoster virus was contact with an 11-year-old sister who did not attend the day-care center and who had herpes zoster (confirmed by Tzanck testing) on her left arm and back beginning on November 10, 2000 (21 days before the onset of rash in the index patient). The index case gave rise to 15 secondary cases in Building A, corresponding to a secondary attack rate of 48.4 percent (15 of 31) overall — 45.8 percent (11 of 24) among vaccinated children and 57.1 percent (4 of 7) among unvaccinated susceptible children.
The Outbreak
The outbreak lasted from December 1, 2000, to January 11, 2001 (Figure 1Figure 1
Cases of Varicella in a New Hampshire Day-Care Center in December 2000 and January 2001, According to the Vaccination Status of the Children and the Date of Onset of Rash.). There were a total of 25 cases of varicella. Seventeen cases (68.0 percent) occurred in vaccinated children and eight cases (32.0 percent) in unvaccinated children at least 12 months of age. There were no cases in infants or children with a history of varicella disease. The median age of children with varicella was 4.4 years (range, 13 months to 7.6 years), and 19 of these children (76.0 percent) were boys (Table 1).Overall, 17 cases of varicella were mild, and 8 cases were moderate or severe. No child had a severe complication of varicella or required hospitalization. As compared with unvaccinated children, those who had been vaccinated had milder disease, had new lesions on fewer days, had rash that crusted more quickly, missed fewer days of day care, and were less likely to have fever (Table 2Table 2
Characteristics of Illness among Vaccinated Children with Varicella and Unvaccinated Children with Varicella.).The outbreak began and was centered in Building A, where 19 cases (76.0 percent) occurred. Of the six cases in children in Building B, three occurred within one incubation period after the index case in Building A, and two other cases were more likely to have resulted from secondary household transmission than transmission at the day-care center — evidence that little if any transmission occurred in Building B. Both cases presumed to have resulted from household transmission occurred in younger siblings of patients who attended day care in Building A, and in both cases, varicella developed 13 to 14 days after the onset of rash in the older sibling. In one family, transmission occurred between unvaccinated siblings, whereas in the other, it occurred between vaccinated siblings.
Vaccine Effectiveness
The cumulative attack rate among continuously enrolled, unvaccinated, susceptible children at least 12 months of age who had attended day care for at least one week was 85.7 percent (6 of 7) in Building A and 18.2 percent (2 of 11) in Building B. When corrected for transmission occurring outside of the building, the attack rate in Building B was 9.1 percent (1 of 11). The attack rate among vaccinated children in Building A was 48.0 percent (12 of 25). Vaccine effectiveness for children in Building A was 44.0 percent (95 percent confidence interval, 6.9 to 66.3 percent) against disease of any severity and 86.0 percent (95 percent confidence interval, 38.7 to 96.8 percent) against moderate-to-severe disease (which occurred in two vaccinated and four unvaccinated children in Building A).
Risk Factors for Vaccine Failure
Two continuous variables — time since vaccination and age at vaccination — were associated with the risk of vaccine failure (Table 3Table 3
Risk Factors for Failure of Varicella Vaccine among Vaccinated Children in Building A Continuously Enrolled and in Attendance for at Least One Week during the Varicella Outbreak.). Children vaccinated three or more years before the start of the outbreak had more than twice the risk of disease found among those vaccinated within three years before the outbreak (relative risk, 2.6 [95 percent confidence interval, 1.3 to 5.3]). Age at vaccination did not remain significantly associated with vaccine failure when it was dichotomized into vaccination at less than 14 months of age and vaccination at older ages (P=0.59).Laboratory Analysis
Two cases were confirmed by laboratory testing, and the remainder were epidemiologically linked. Wild-type varicella was cultured from an unvaccinated child in Building A with an onset of rash on December 25, 2000, and wild-type varicella was detected by polymerase-chain-reaction analysis of a papule from the vaccinated child in Building B who had the last case in the outbreak.
Reliability of the Absence of a History of Varicella
Seven children who did not have varicella were reported by parents to be susceptible to it. All four whose parents agreed to serologic testing were seronegative, including the only child in Building A whose history suggested susceptibility but in whom varicella did not develop.
Storage and Handling of Vaccine
Periodic evaluation of the storage and handling of vaccine in the offices of vaccine providers, conducted by the state health department since the licensure of the vaccine, did not identify substantial problems. The vaccine is distributed directly from the manufacturer to the clinics and offices that provide vaccination without reliance on redistribution centers.
Discussion
In this outbreak, the effectiveness of the varicella vaccine was 44 percent against disease of any severity and 86 percent against moderate and severe disease — significantly lower than that found in any previous investigation. We found an increased risk of vaccine failure among children vaccinated three or more years previously. The index patient was a healthy vaccinated child who infected more than 50 percent of susceptible classmates, indicating that breakthrough disease can be highly infectious.
The reasons for the poor performance of the vaccine are not apparent. The thermolability of the vaccine raised concern about lapses in vaccine storage and handling, although no substantial deficiencies were detected over time or after the outbreak was recognized. Furthermore, we found no clustering of breakthrough cases according to the lot number of the vaccine used, the year of vaccination, the clinic, or the medical provider that might suggest the use of an ineffective lot of vaccine or problems with storage, handling, or administration.
Univariate analysis identified time since vaccination as a risk factor for vaccine failure. Children vaccinated three or more years before the start of the outbreak had a risk of breakthrough disease that was more than twice as high as that among children vaccinated more recently. A younger age at vaccination (less than 14 months), which has previously been identified as a risk factor,5,6 was not associated with an increased risk of vaccine failure, nor did we detect an association with asthma or other coexisting conditions. However, in Building A, only three children were vaccinated at less than 14 months of age, three children with varicella had asthma, and two children with varicella had coexisting conditions (one had IgA deficiency, and the other had epilepsy).
We used data from Building A to estimate vaccine effectiveness and determine risk factors for vaccine failure. The cumulative attack rate among unvaccinated, susceptible children 12 months of age or older was approximately 86 percent in Building A and 9 percent in Building B. The low attack rate in Building B suggests that most children in this building were never exposed to varicella. Since the calculation of vaccine effectiveness relies on an assumption of equal exposure to disease, data from children in Building B were excluded from the calculations. The cases in children in Building B probably resulted from contact that occurred outside the classroom or from household exposure.
This outbreak began with disease in a vaccinated child who infected more than half his classmates who had no history of varicella. His attendance at day care for two days before the onset of rash and only brief attendance on the morning on which his rash erupted suggest that transmission occurred by airborne spread. Our findings also suggest that it is not possible to identify in advance persons who could be highly infectious were they to have breakthrough disease, a fact of particular concern in hospitals and other settings that rely on vaccine-derived immunity to protect against the acquisition and transmission of varicella. It is possible that vaccinated persons in whom a large number of vesicular lesions develop when they are exposed to a patient with an infectious case of varicella or herpes zoster may be more infectious than persons who have nonvesicular lesions or fewer lesions overall, although this question requires further study.
There are a number of limitations to our study. This outbreak and others that come to the attention of public health officials may represent extreme situations and result in underestimates of the effectiveness of the vaccine.23 Even so, the upper confidence limit of our estimate was below the lower limit of the expected range of effectiveness for varicella vaccine. We relied on reports of rash by parents or physicians for diagnosis in most cases, a method that may have resulted in an overestimate or underestimate of the effectiveness of the vaccine. Incorrect diagnosis of conditions commonly mistaken for breakthrough disease (such as insect bites or enteroviral infections) could have falsely lowered the estimate of vaccine effectiveness, although these conditions occur infrequently in midwinter. Subtle presentations of breakthrough disease that were not clinically recognized could have led to a false elevation of the estimate of vaccine effectiveness. Finally, the small number of children in the day-care center limited our ability to explore the independent effects of the time since vaccination and the age at vaccination in multivariate analyses.
Although policy cannot be established on the basis of one outbreak, the findings in this investigation raise concern that the current vaccination strategy may not protect all children adequately. Further investigations are needed to define more clearly the range of effectiveness of the vaccine and risk factors for vaccine failure. In a number of prelicensure studies, persons who did not have an adequate immune response after vaccination were revaccinated,13 excluded from the analysis of vaccine efficacy,10,14 or analyzed separately,11 potentially inflating the estimate by the removal of persons who had primary vaccine failure.
Although the vaccine provided suboptimal protection against varicella in this outbreak, it provided robust protection against moderate and severe varicella and has reduced the incidence of varicella dramatically in the United States.14 Given the approximately 11,000 hospitalizations24 and 100 deaths25 due to varicella that occurred annually in the era before vaccination, vaccination remains the most effective strategy for protecting children and adults against illness and death due to varicella.
Presented in part at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 15–19, 2001.
We are indebted to the staff of the day-care center, its attendees, and their parents for their participation; to the medical providers for providing timely and detailed medical information; to Dr. Jesse Greenblatt and the staff of the New Hampshire Department of Health and Human Services for their help in the field; to Drs. Scott Schmid and Vladimir Loparev of the National Varicella Reference Laboratory (Centers for Disease Control and Prevention) for laboratory testing of specimens; and to Dr. John Zhang for assistance with data management.
Source Information
From the Centers for Disease Control and Prevention, Atlanta (K.G., B.L., T.S., A.L.B., J.S.); the New Hampshire Department of Health and Human Services, Concord (C.C., J.M.); and the College of Veterinary Medicine, Washington State University, Pullman (M.E.).
Address reprint requests to Dr. Galil at 65 Hayden Ave., Lexington, MA 02421, or at karin.galil@cubist.com.
- References
References
1
Izurieta HS ,Strebel PM ,Blake PA . Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495-1499
CrossRef | Web of Science | Medline2
Buchholz U ,Moolenaar R ,Peterson C ,Mascola L . Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics 1999;104:561-563
CrossRef | Web of Science | Medline3
Clements DA ,Moreira SP ,Coplan PM ,Bland CL ,Walter EB . Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 1999;18:1047-1050
CrossRef | Web of Science | Medline4
Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice.N Engl J Med 2001;344:955-60.
5
Galil K ,Fair E ,Mountcastle N ,Britz P ,Seward J . Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002;186:102-105
CrossRef | Web of Science | Medline6
Dworkin MS ,Jennings CE ,Roth-Thomas J ,Lang JE ,Stukenberg C ,Lumpkin JR . An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis 2002;35:102-104
CrossRef | Web of Science | Medline7
Weibel RE ,Neff BJ ,Kuter BJ , et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984;310:1409-1415
Full Text | Web of Science | Medline8
Arbeter AM ,Starr SE ,Plotkin SA . Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78:748-756
Web of Science | Medline9
Johnson CE ,Shurin PA ,Fattlar D ,Rome LP ,Kumar ML . Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics 1988;81:512-518
Web of Science | Medline10
Johnson C ,Rome LP ,Stancin T ,Kumar ML . Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989;84:418-421
Web of Science | Medline11
White CJ ,Kuter BJ ,Hildebrand CS , et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991;87:604-610
Web of Science | Medline12
Kuter BJ ,Weibel RE ,Guess HA , et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-647
CrossRef | Web of Science | Medline13
Clements DA ,Armstrong CB ,Ursano AM ,Moggio MM ,Walter EB ,Wilfert CM . Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995;14:874-879
CrossRef | Web of Science | Medline14
Johnson CE ,Stancin T ,Fattlar D ,Rome LP ,Kumar ML . A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997;100:761-766
CrossRef | Web of Science | Medline15
Seward JF ,Watson BM ,Peterson CL , et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002;287:606-611
CrossRef | Web of Science | Medline16
Rothstein EP ,Bernstein HH ,Ngai AL ,Cho I ,White CJ . Dose titration study of live attenuated varicella vaccine in healthy children. J Infect Dis 1997;175:444-447
CrossRef | Web of Science | Medline17
Galil K ,Watson B ,Peterson C , et al. Breakthrough varicella cases since vaccine licensure in the Varicella Active Surveillance Project. Pediatr Res 2001;49:Suppl 2:150A-150A abstract.18
Watson BM ,Piercy SA ,Plotkin SA ,Starr SE . Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22
Web of Science | Medline19
National, state, and urban area vaccination coverage levels among children aged 19-35 months -- United States, 2000. MMWR Morb Mortal Wkly Rep 2001;50:637-641
Medline20
Loparev VN ,Argaw T ,Krause PR ,Takayama M ,Schmid DS . Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 2000;38:3156-3160
Web of Science | Medline21
LaRussa P ,Lungu O ,Hardy I ,Gershon A ,Steinberg SP ,Silverstein S . Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992;66:1016-1020
Web of Science | Medline22
Orenstein WA ,Bernier RH ,Dondero TJ , et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985;63:1055-1068
Web of Science | Medline23
Fine PE ,Zell ER . Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol 1994;139:77-90
Web of Science | Medline24
Galil K ,Brown C ,Lin F ,Seward J . Hospitalizations for varicella in the United States, 1988 to 1995. Pediatr Infect Dis J 2002;21:931-935
CrossRef | Web of Science | Medline25
Meyer PA ,Seward JF ,Jumaan AO ,Wharton M . Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182:383-390
CrossRef | Web of Science | Medline
- Citing Articles (73)
Citing Articles
1
Joanne F. Chou, Nancy A. Kernan, Susan Prockop, Glenn Heller, Andromachi Scaradavou, Rachel Kobos, Molly A. Knowles, Esperanza B. Papadopoulos, Anne Casson, Catherine Copeland, Joanne Torok-Castanza, Nicole Zakak, Julianne Ruggiero, Trudy N. Small. (2011) Safety and Immunogenicity of the Live Attenuated Varicella Vaccine Following T Replete or T Cell-Depleted Related and Unrelated Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biology of Blood and Marrow Transplantation 17:11, 1708-1713
CrossRef2
Markus Knuf, Fred Zepp, Klaus Helm, Hartwig Maurer, Albrecht Prieler, Dorothee Kieninger-Baum, Martine Douha, Paul Willems. (2011) Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children. European Journal of Pediatrics
CrossRef3
Zafer Kurugol, Oya Halicioglu, Feyza Koc, Guldane Koturoglu, Sadik Aksit. (2011) Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey. International Journal of Infectious Diseases 15:7, e475-e480
CrossRef4
H.C. Rümke, H.P. Loch, K. Hoppenbrouwers, C. Vandermeulen, A. Malfroot, K. Helm, M. Douha, P. Willems. (2011) Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine 29:22, 3842-3849
CrossRef5
Wen-Chan Huang, Li-Min Huang, I-Shou Chang, Fang-Yu Tsai, Luan-Yin Chang. (2011) Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine 29:15, 2756-2760
CrossRef6
Marco Ajelli, Laura Fumanelli, Piero Manfredi, Stefano Merler. (2011) Spatiotemporal dynamics of viral hepatitis A in Italy. Theoretical Population Biology 79:1-2, 1-11
CrossRef7
Chao-Chih Lai, Szu-Ching Chen, Donald Jiang. (2011) An Outbreak of Varicella among Schoolchildren in Taipei. BMC Public Health 11:1, 226
CrossRef8
Luan-Yin Chang, Li-Min Huang, I-Shou Chang, Fang-Yu Tsai. (2011) Epidemiological Characteristics of Varicella from 2000 to 2008 and the impact of nationwide immunization in Taiwan. BMC Infectious Diseases 11:1, 352
CrossRef9
Chuanxi Fu, Ming Wang, Jianhua Liang, Jianxiong Xu, Chengbin Wang, Stephanie Bialek. (2010) The Effectiveness of Varicella Vaccine in China. The Pediatric Infectious Disease Journal 29:8, 690-693
CrossRef10
Marco Ajelli, Stefano Merler. (2009) An individual-based model of hepatitis A transmission. Journal of Theoretical Biology 259:3, 478-488
CrossRef11
Scott A. Halperin, Giuseppe Ferrera, David Scheifele, Gerald Predy, Giuseppe Stella, Mario Cuccia, Martine Douha, Paul Willems. (2009) Safety and immunogenicity of a measles–mumps–rubella–varicella vaccine given as a second dose in children up to six years of age. Vaccine 27:20, 2701-2706
CrossRef12
(2009) Empfehlung einer generellen Zweitimpfung gegen Varizellen. Monatsschrift Kinderheilkunde 157:4, 377-379
CrossRef13
Y. Gillet, G.C. Steri, U. Behre, J.P. Arsène, X. Lanse, K. Helm, S. Esposito, N. Meister, M.G. Desole, M. Douha, P. Willems. (2009) Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine 27:3, 446-453
CrossRef14
O. Picone, C. Vauloup-Fellous, M. V. Senat, R. Frydman, L. Grangeot-Keros. (2008) Maternal varicella infection during pregnancy in a vaccinated patient. Prenatal Diagnosis 28:10, 971-972
CrossRef15
Ayşe Kiliç, Emin Ünüvar, Ceren Yilmaz, Ismail Yildiz, Fatma Oğuz, Mujgan Sidal. (2008) The effectiveness of varicella vaccination during an outbreak in a childrens’ day-care center. Vaccine 26:27-28, 3371-3372
CrossRef16
Eugene D. Shapiro. (2008) Second Dose of Varicella Vaccine for Children: Are We Giving It Too Late?. The Journal of Infectious Diseases 197:7, 935-937
CrossRef17
David E. Michalik, Sharon P. Steinberg, Philip S. LaRussa, Kathryn M. Edwards, Peter F. Wright, Ann M. Arvin, Haley A. Gans, Anne A. Gershon. (2008) Primary Vaccine Failure after 1 Dose of Varicella Vaccine in Healthy Children. The Journal of Infectious Diseases 197:7, 944-949
CrossRef18
Sandra S. Chaves, John Zhang, Rachel Civen, Barbara M. Watson, Tina Carbajal, Dana Perella, Jane F. Seward. (2008) Varicella Disease among Vaccinated Persons: Clinical and Epidemiological Characteristics, 1997–2005. The Journal of Infectious Diseases 197:s2, S127-S131
CrossRef19
Steve Black, Paula Ray, Henry Shinefield, Patricia Saddier, Alexander Nikas. (2008) Lack of Association between Age at Varicella Vaccination and Risk of Breakthrough Varicella, within the Northern California Kaiser Permanente Medical Care Program. The Journal of Infectious Diseases 197:s2, S139-S142
CrossRef20
Rachel Civen, Adriana S. Lopez, John Zhang, Jorge Garcia‐Herrera, D. Scott Schmid, Sandra S. Chaves, Laurene Mascola. (2008) Varicella Outbreak Epidemiology in an Active Surveillance Site, 1995–2005. The Journal of Infectious Diseases 197:s2, S114-S119
CrossRef21
Henry R. Shinefield, Steve Black, Barbara J. Kuter. (2008) Varicella Immunogenicity with 1‐ and 2‐Dose Regimens of Measles‐Mumps‐Rubella‐Varicella Vaccine. The Journal of Infectious Diseases 197:s2, S152-S155
CrossRef22
Jane F. Seward, Mona Marin, Marietta Vázquez. (2008) Varicella Vaccine Effectiveness in the US Vaccination Program: A Review. The Journal of Infectious Diseases 197:s2, S82-S89
CrossRef23
Luis Salleras Sanmartí, Monserrat Salleras Redonnet, Andrés Prat, Patricio Garrido, Ángela Domínguez. (2008) Vacunas frente al virus de la varicela zóster. Enfermedades Infecciosas y Microbiología Clínica 26, 29-47
CrossRef24
Sohita Dhillon, Monique P Curran. (2008) Live Attenuated Measles, Mumps, Rubella, and Varicella Zoster Virus Vaccine (Priorix-Tetra™). Pediatric Drugs 10:5, 337-347
CrossRef25
Trudy Small. (2008) Vaccination of Children following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 14:1, 54-58
CrossRef26
Nitu Sengupta, Robert Booy, H. J. Schmitt, Heikki Peltola, Pierre Van-Damme, R. Fabian Schumacher, Magda Campins, Carlos Rodrigo, Terho Heikkinen, Jane Seward, Aisha Jumaan, Adam Finn, Per Olcén, Nancy Thiry, Catherine Weil-Olivier, Judith Breuer. (2007) Varicella vaccination in Europe: are we ready for a universal childhood programme?. European Journal of Pediatrics 167:1, 47-55
CrossRef27
Linda M. Niccolai, Lorraine G. Ogden, Catherine E. Muehlenbein, James D. Dziura, Marietta Vázquez, Eugene D. Shapiro. (2007) Methodological issues in design and analysis of a matched case–control study of a vaccine's effectiveness. Journal of Clinical Epidemiology 60:11, 1127-1131
CrossRef28
Otmar Bayer, Ulrich Heininger, Cora Heiligensetzer, Rüdiger von Kries. (2007) Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine 25:37-38, 6655-6660
CrossRef29
Timo Vesikari, Catherine Sadzot-Delvaux, Bernard Rentier, Anne Gershon. (2007) Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe. The Pediatric Infectious Disease Journal 26:7, 632-638
CrossRef30
Jeffrey L. Silber, Ivan S. F. Chan, William W. Wang, Holly Matthews, Barbara J. Kuter. (2007) Immunogenicity of Oka/Merck Varicella Vaccine in Children Vaccinated at 12???14 Months of Age Versus 15???23 Months of Age. The Pediatric Infectious Disease Journal 26:7, 572-576
CrossRef31
Hassan Vally, Gary K. Dowse, Keith Eastwood, Scott Cameron. (2007) An outbreak of chickenpox at a child care centre in Western Australia. Costs to the community and implications for vaccination policy. Australian and New Zealand Journal of Public Health 31:2, 113-119
CrossRef32
Chaves, Sandra S., Gargiullo, Paul, Zhang, John X., Civen, Rachel, Guris, Dalya, Mascola, Laurene, Seward, Jane F., . (2007) Loss of Vaccine-Induced Immunity to Varicella over Time. New England Journal of Medicine 356:11, 1121-1129
Full Text33
J.A. Stockman. (2007) Vaccine Effectiveness During a Varicella Outbreak Among Schoolchildren: Utah, 2002-2003. Yearbook of Pediatrics 2007, 261-263
CrossRef34
Elizabeth Peadon, David Burgner, Michael Nissen, Jim Buttery, Yvonne Zurynski, Elizabeth Elliott, Michael Gold, Helen Marshall, Robert Booy. (2006) Case for varicella surveillance in Australia. Journal of Paediatrics and Child Health 42:11, 663-664
CrossRef35
Ulrich Heininger, Jane F Seward. (2006) Varicella. The Lancet 368:9544, 1365-1376
CrossRef36
Lawrence A. Hunt. 2006. Cytomegalovirus and Varicella-Zoster Virus Vaccines. .
CrossRef37
Navin Paul, Mini E. Jacob. (2006) An Outbreak of Cadaver‐Acquired Chickenpox in a Health Care Setting. Clinical Infectious Diseases 43:5, 599-601
CrossRef38
Alberto Arnedo-Pena, Joan Puig-Barber??, Mar??a Amparo Aznar-Orenga, Manuel Ballester-Albiol, Francisco Pardo-Serrano, Juan Bautista Bellido-Blasco, Mar??a Angeles Romeu-Garc??a. (2006) Varicella Vaccine Effectiveness During an Outbreak in a Partially Vaccinated Population in Spain. The Pediatric Infectious Disease Journal 25:9, 774-778
CrossRef39
Hein J. Boot, Hester E. de Melker, Elly A. Stolk, G. Ardine de Wit, Tjeerd G. Kimman. (2006) Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 24:37-39, 6288-6299
CrossRef40
David E. Michalik, Anne A. Gershon. (2006) Zoster vaccine for the elderly. Drug Discovery Today: Therapeutic Strategies 3:2, 237-241
CrossRef41
Ann Arvin, Anne Gershon. (2006) Control of Varicella. The Pediatric Infectious Disease Journal 25:6, 475-476
CrossRef42
Hung-Fu Tseng, Hsiu-Fen Tan, Chen-Kang Chang. (2006) Use of National Health Insurance database to evaluate the impact of public varicella vaccination program on burden of varicella in Taiwan. Vaccine 24:25, 5341-5348
CrossRef43
Matthew M Davis. (2006) Successes and remaining challenges after 10 years of varicella vaccination in the USA. Expert Review of Vaccines 5:2, 295-302
CrossRef44
Markus Knuf, Pirmin Habermehl, Fred Zepp, Wilma Mannhardt, Martin Kuttnig, Pekka Muttonen, Albrecht Prieler, Hartwig Maurer, Helmtrud Bisanz, Nadia Tornieporth, Dominique Descamps, Paul Willems. (2006) Immunogenicity and Safety of Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children. The Pediatric Infectious Disease Journal 25:1, 12-18
CrossRef45
Sung Hee Oh. (2006) Update in varicella vaccination. Korean Journal of Pediatrics 49:3, 229
CrossRef46
Heather F. Gidding, Marc Brisson, C. Raina Macintyre, Margaret A. Burgess. (2005) Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Australian and New Zealand Journal of Public Health 29:6, 544-551
CrossRef47
KK Macartney, P Beutels, P McIntyre, MA Burgess. (2005) Varicella vaccination in Australia. Journal of Paediatrics and Child Health 41:11, 544-552
CrossRef48
J. Ramet, C. Weil-Olivier, W. Sedlak. (2005) Is Europe ready to embrace a policy of universal varicella vaccination?*. International Journal of Clinical Practice 59:11, 1326-1333
CrossRef49
R. G. Pebody. (2005) Universal varicella-zoster vaccination: is Europe ready?. International Journal of Clinical Practice 59:11, 1248-1250
CrossRef50
Mary Anne Jackson, Angela Myers. (2005) Vaccines in the Pipeline. Pediatric Emergency Care 21:11, 777-783
CrossRef51
Susan S Chiu, Yu-Lung Lau. (2005) Review of the Varilrix™ varicella vaccine. Expert Review of Vaccines 4:5, 629-643
CrossRef52
Richard Kent Zimmerman, Melissa Tabbarah, Barbara Bardenheier, Janine E. Janosky, Judith A. Troy, Mahlon Raymund, Barbara P. Yawn. (2005) The 2002 United States varicella vaccine shortage and physician recommendations for vaccination. Preventive Medicine 41:2, 575-582
CrossRef53
Gary Goldman. (2005) Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster. International Journal of Toxicology 24:4, 205-213
CrossRef54
Charles Grose. (2005) Varicella vaccination of children in the United States: Assessment after the first decade 1995–2005. Journal of Clinical Virology 33:2, 89-95
CrossRef55
Judith Breuer. (2005) Commentary on varicella vaccination of children in the United States: Assessment after the first decade 1995–2005. Journal of Clinical Virology 33:2, 96-98
CrossRef56
Anne Malfroot, Georgios Adam, Oana Ciofu, Gerd Döring, Christiane Knoop, Aloïs B. Lang, Pierre Van Damme, Isi Dab, Andrew Bush. (2005) Immunisation in the current management of cystic fibrosis patients. Journal of Cystic Fibrosis 4:2, 77-87
CrossRef57
Rivka Sheffer, Danit Segal, Sarit Rahamani, Ilan Dalal, Yifat Linhart, Michal Stein, Tamar Shohat, Eli Somekh. (2005) Effectiveness of the Oka/GSK Attenuated Varicella Vaccine for the Prevention of Chickenpox in Clinical Practice in Israel. The Pediatric Infectious Disease Journal 24:5, 434-437
CrossRef58
(2005) Indications for varicella vaccination post-transplant. Pediatric Transplantation 9:2, 141-144
CrossRef59
Dan Miron, Idit Lavi, Rachel Kitov, Avishag Hendler. (2005) Vaccine Effectiveness and Severity of Varicella Among Previously Vaccinated Children During Outbreaks in Day-Care Centers With Low Vaccination Coverage. The Pediatric Infectious Disease Journal 24:3, 233-236
CrossRef60
Barbara Watson. (2005) Varicella-zoster vaccine in the USA: success for control of disease severity, but what next?. Expert Review of Anti-infective Therapy 3:1, 105-115
CrossRef61
Demian Christiansen, Elizabeth D. Barnett. (2004) Comparison of varicella history with presence of varicella antibody in refugees. Vaccine 22:31-32, 4233-4237
CrossRef62
Matthias Budt, Henrike Reinhard, Arndt Bigl, Hartmut Hengel. (2004) Herpesviral Fcγ receptors: culprits attenuating antiviral IgG?. International Immunopharmacology 4:9, 1135-1148
CrossRef63
Gary S. Goldman. (2004) Response to Letter to the Editor by Jumaan. Vaccine 22:25-26, 3232-3236
CrossRef64
Marietta Vázquez. (2004) Varicella Infections and Varicella Vaccine in the 21st Century. The Pediatric Infectious Disease Journal 23:9, 871-872
CrossRef65
Shaine A Morris, Henry H Bernstein. (2004) Immunizations, neonatal jaundice, and animal-induced injuries. Current Opinion in Pediatrics 16:4, 450-460
CrossRef66
JUSTEN H. PASSWELL, BEATRICE HEMO, YONIT LEVI, REUT RAMON, NURIT FRIEDMAN, LIAT LERNER-GEVA. (2004) Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. The Pediatric Infectious Disease Journal 23:3, 221-226
CrossRef67
John P Mullooly, Julie E Maher, Lois Drew, Roberleigh Schuler, Weiming Hu. (2004) Evaluation of the impact of an HMO’s varicella vaccination program on incidence of varicella. Vaccine 22:11-12, 1480-1485
CrossRef68
Michiaki Takahashi. (2004) Effectiveness of live varicella vaccine. Expert Opinion on Biological Therapy 4:2, 199-216
CrossRef69
Marietta V??zquez. (2004) Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine. Current Opinion in Pediatrics 16:1, 80-84
CrossRef70
S. M. Mackell. (2003) Vaccinations for the Pediatric Traveler. Clinical Infectious Diseases 37:11, 1508-1516
CrossRef71
Graham A. Tipples, David Safronetz, Michael Gray. (2003) A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains. Journal of Virological Methods 113:2, 113-116
CrossRef72
(2003) An Outbreak of Varicella despite Vaccination. New England Journal of Medicine 348:14, 1405-1407
Full Text73
Gershon, Anne A., . (2002) Varicella Vaccine — Are Two Doses Better Than One?. New England Journal of Medicine 347:24, 1962-1963
Full Text
- Letters
